| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565] | Technology appraisal guidance |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764] | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763] | Technology appraisal guidance |
| Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID12198] | Technology appraisal guidance |
| Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433] | Technology appraisal guidance |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237] | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454] | Technology appraisal guidance |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance |
| Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib
[ID6494] | Technology appraisal guidance |
| Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163] | Technology appraisal guidance |
| Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825] | Technology appraisal guidance |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385] | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes [ID1450] | Technology appraisal guidance |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older
[ID6542] | Technology appraisal guidance |
| Sibeprenlimab for treating IgA nephropathy [TSID12111] | Technology appraisal guidance |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147] | Technology appraisal guidance |
| Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536] | Technology appraisal guidance |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions | Medical technologies guidance |
| Staged bilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | Interventional procedures guidance |
| STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278] | Technology appraisal guidance |
| STS101 for treating acute migraine [TSID11782] | Technology appraisal guidance |
| Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977] | Technology appraisal guidance |
| Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081 | Technology appraisal guidance |
| Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568] | Technology appraisal guidance |
| Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments [ID6413] | Technology appraisal guidance |
| Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460] | Technology appraisal guidance |
| Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191] | Technology appraisal guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918] | Technology appraisal guidance |
| The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound | Medical technologies guidance |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217] | Technology appraisal guidance |
| Tirzepatide for treating type 2 diabetes in people 10 to 17 years
[TSID12131] | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683] | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance |